Late Presentation and Loss to Follow-Up of Immigrants Newly Diagnosed with HIV in the HAART Era
- 230 Downloads
To compare clinical characteristics and therapeutic management of newly HIV-diagnosed immigrants to natives. Patients with a first HIV diagnosis from 1996 to 2010 were included. Of 716 new diagnoses, 85 (12 %) were immigrants. Migrants were younger, more frequently females and sexually infected, less likely to voluntarily request testing, and less HCV-coinfected. Late presenters (CD4 <350 or AIDS) were 76 % among migrants versus 56 % in natives (p = 0.006) with an increasing trend over time. HAART was initiated in 76.5 % of natives and 72.4 % of immigrants; the number/type of adverse events and treatment discontinuation were similar. Immigrants received more NNRTIs-based regimens. A similar proportion of patients reached virological suppression at month 1–3–6 after HAART initiation, but 43 % of immigrants versus 27 % of natives resulted lost to follow-up (p < 0.001). Diagnosis of HIV was often delayed among migrants, who also presented a higher rate of lost to follow-up.
KeywordsHIV/AIDS Immigrants Late presenters HAART
We gratefully acknowledge Mrs. Paulene Butts for the helpful review of the manuscript.
- 1.Istituto Superiore Di Sanità (ISS)-Centro Operativo AIDS (CoA). Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 Dicembre 2011. Not Ist Super Sanità. 2012;25(10 Suppl 1):3–46.Google Scholar
- 3.Pérez Molina JA, Rillo MM, Suárez-Lozano I, Casado Osorio JL, Cobo RT, González PR, Clotet EP, Jerez AH, Pedrol PD, Royuela A, Díaz EB, Esteban H, González-García J. Do HIV-infected immigrants initiating HAART have poorer treatment-related outcomes than autochthonous patients in Spain? Results of the GESIDA 5808 Study. Curr HIV Res. 2010;8(7):521–30.PubMedCrossRefGoogle Scholar
- 5.Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D’Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–29.PubMedCrossRefGoogle Scholar
- 6.Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Staehelin C, Keiser O, Calmy A, Weber R, Elzi L, Cavassini M, Schmid P, Bernasconi E, Furrer H, Swiss HIV Cohort Study. Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2012;59(1):79–85.PubMedCrossRefGoogle Scholar
- 9.Yebra G, de Mulder M, Pérez-Elías MJ, Pérez-Molina JA, Galán JC, Llenas-García J, Moreno S, Holguín A. Increase of transmitted drug resistance among HIV-infected Sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One. 2011;6(10):e26757.PubMedCentralPubMedCrossRefGoogle Scholar